Fundz

Bolt Biotherapeutics

Redwood City, California, United States · Biotechnology, Other

Bolt Biotherapeutics is a Nasdaq-listed (BOLT) biotechnology company. It announced the acquisition of Prana Therapies alongside a $120 million concurrent private placement. The company will advance Prana's PRA-216 pipeline in inflammatory indications.

Key facts

Headquarters
Redwood City, California, United States
Employees
23
Industries
Biotechnology, Other
Status
Public (BOLT)
Website
boltbio.com

Recent activity at Bolt Biotherapeutics

  • : Bolt Biotherapeutics Appoints Sheila Gujrathi as Chief Strategy Officer
  • : Bolt Biotherapeutics acquires Prana Therapies
  • : SEC 8-K (5.02): On October 23, 2026, Dr. Sheila Gujrathi was appointed to the Board as a Class II director, effective immediately after the Merger Agreement's First Effective Time. Dr. Gujrathi, age 56, is the founder and CEO of Prana Therapies and also serves as Executive Chair of Lila Biologics, Inc. She has extensive experience in the biopharmaceutical industry, holding various leadership roles on the boards of numerous companies, such as Processa Pharmaceuticals and BlossomHill Therapeutics. This appointment is part of a strategic move to strengthen the board with Dr. Gujrathi's significant expertise in the biopharmaceutical sector.
  • : SEC 8-K (1.01): On October 1, 2026, Bolt Biotherapeutics, Inc. entered into the Second Amendment to Lease with HCP LS Redwood City LLC, modifying a previous lease agreement for their corporate office and laboratory facilities. The Company paid $1.0 million to the Landlord and agreed to let the Landlord draw a $1.5 million letter of credit. Additionally, both parties set an accelerated lease expiration date of December 31, 2027, contingent upon a Corporate Transaction, which would trigger an additional $4.5 million termination payment. The company’s ongoing financial obligations related to rent and operating expenses have been deemed not significant, and the company will continue subleasing arrangements while remitting all sublease rent to the Landlord.
  • : Bolt Biotherapeutics, Inc.
  • : Bolt Biotherapeutics, Inc.
  • : Bolt Biotherapeutics, Inc.
  • : Bolt Biotherapeutics, Inc.
  • : Bolt Biotherapeutics, Inc.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Bolt Biotherapeutics funding history

DateRoundAmount
Jun 2021Venture$15.0M
Jan 2021Venture$93.5M
Jul 2019Venture$40.1M
Aug 2018Venture$13.4M
Feb 2018Venture$6.0M

Leadership

  • Michael, Scientific Co-founder & Senior Vice President, Research
  • Ron, Sr. Director Quality
  • Randall Schatzman, Executive Officer, Director
  • Edgar Engleman, Director
  • Ashish Khanna, Director
  • Richard Miller, Director
  • James Healy, Director
  • Mahendra Shah, Director
  • Kathleen LaPorte, Director
  • Peter Moldt, Director

Verified email and direct lines for Bolt Biotherapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Bolt Biotherapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Companies similar to Bolt Biotherapeutics

About Bolt Biotherapeutics: questions and answers

What does Bolt Biotherapeutics do?

Bolt Biotherapeutics is a Nasdaq-listed (BOLT) biotechnology company. It announced the acquisition of Prana Therapies alongside a $120 million concurrent private placement. The company will advance Prana's PRA-216 pipeline in inflammatory indications.

Where is Bolt Biotherapeutics headquartered?

Bolt Biotherapeutics is headquartered in Redwood City, California, United States.

How many employees does Bolt Biotherapeutics have?

Bolt Biotherapeutics has about 23 employees.

Has Bolt Biotherapeutics raised funding?

Yes. Fundz has recorded 5 funding events for Bolt Biotherapeutics. The most recent, $15.0M, was in Jun 2021.

Who leads Bolt Biotherapeutics?

Michael is a Scientific Co-founder & Senior Vice President, Research at Bolt Biotherapeutics.

What is the latest news on Bolt Biotherapeutics?

On Oct 25, 2026, Bolt Biotherapeutics Appoints Sheila Gujrathi as Chief Strategy Officer

Is Bolt Biotherapeutics a public company?

Yes. Bolt Biotherapeutics is publicly traded under the ticker BOLT.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Bolt Biotherapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.